The Claim
In postmenopausal women receiving estrogen replacement therapy, long-term suppressive levothyroxine therapy (150–184 mcg/day for 3–5 years) has no significant effect on bone mineral density or osteocalcin levels when compared to matched controls.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In postmenopausal women taking estrogen therapy, long-term high-dose levothyroxine does not change bone density or osteocalcin levels compared to similar women not taking levothyroxine.
See the scientific wording
In postmenopausal women receiving estrogen replacement therapy, long-term suppressive levothyroxine therapy (150–184 mcg/day for 3–5 years) does not significantly affect bone mineral density or osteocalcin levels compared to matched controls, suggesting that estrogen may mitigate potential skeletal effects of thyroid hormone excess.
Estrogen blocks the cells that break down bone, so even when thyroid hormone tries to speed up bone loss, the bones stay strong because the breaking-down cells are kept in check.
What the research says
1 studyIn women who’ve gone through menopause and are taking estrogen, even high doses of thyroid hormone for years didn’t weaken their bones or increase bone breakdown markers — suggesting estrogen might protect their bones from the thyroid hormone’s effects.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.